Instructions for use

Title
Inhibitory effects of dopamine on spinal synaptic transmission via dopamine D1-like receptors in neonatal rats

Author(s)
Kawamoto, K.; Otsuguro, K.; Ishizuka, M.; Ito, S.

Citation
British Journal of Pharmacology, 166(2): 788-800

Issue Date
2012-05

Doc URL
http://hdl.handle.net/2115/52711

Rights
The definitive version is available at http://onlinelibrary.wiley.com

Type
article (author version)

File Information
BJP166-2_788-800.pdf
Inhibitory effects of dopamine on spinal synaptic transmission via dopamine D1-like receptors in neonatal rats

K Kawamoto¹, K Otsuguro¹, M Ishizuka² and S Ito¹

Running title: Effects of dopamine on spinal transmission

¹Laboratory of Pharmacology and ²Laboratory of Toxicology, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo 060-0818, Japan

Total number of words: 6,655

Figure count: 11

Correspondence Ken'ichi Otsuguro: Laboratory of Pharmacology, Graduate School of Veterinary Medicine, Hokkaido University, Kita 18, Nishi 9, Sapporo 060-0818, Japan.

Tel. & Fax.: +81·11·706·5220 E·mail address: otsuguro@vetmed.hokudai.ac.jp
BACKGROUND AND PURPOSE

Dopamine released from the endings of the descending dopaminergic fibre in the spinal cord is suggested to be involved in modulating functions such as locomotion and nociception. Here, we examined the effects of dopamine on spinal synaptic transmissions in rats.

EXPERIMENTAL APPROACH

Spinal reflex potentials, monosynaptic reflex potential (MSR) and slow ventral root potential (sVRP), were measured in the isolated spinal cord of the neonatal rat. Dopamine release was measured by using HPLC.

KEY RESULTS

Dopamine at lower concentrations (<1 µM) depressed sVRP, which is C fibre-evoked polysynaptic response and believed to reflect nociceptive transmission. At higher concentrations (>1 µM), in addition to a potent sVRP depression, dopamine depolarized baseline potential and slightly depressed MSR. Depression of sVRP by dopamine was partially reversed by dopamine D1-like but not by D2-like receptor antagonists. SKF83959 and SKF81297, D1-like receptor agonists, and methamphetamine, an endogenous dopamine releaser, also caused the inhibition of sVRP. Methamphetamine also depressed MSR, which was inhibited by ketanserin, a 5-HT_{2A/2C} receptor
antagonist. Methamphetamine induced the release of dopamine and 5-HT from spinal cords, indicating that the release of endogenous dopamine and 5-HT depresses sVRP and MSR, respectively.

**CONCLUSION AND IMPLICATIONS**

These results suggest that dopamine at lower concentrations preferentially inhibits sVRP, which is mediated via D1-like and unidentified receptors. The dopamine-evoked depression is involved in modulating the spinal functions by the descending dopaminergic pathways.

**Keywords** dopamine; D1-like receptors; spinal cord; reflex potentials

**Abbreviations** ACSF, artificial cerebrospinal fluid; DRG, dorsal root ganglion; MSR, monosynaptic reflex potential; PI, phosphatidylinositol; sVRP, slow ventral root potential

**Introduction**

Dopamine is a neurotransmitter in the CNS. Dopamine receptors are classified into five subtypes, referred to as either D1-like (D1 and D5) or D2-like (D2, D3 and D4) receptors
(Missale et al., 1998). Dopamine concentration is a key factor in the activation of different receptor subtypes. In the prefrontal cortex, low concentrations of dopamine act on D1-like receptors, while higher concentrations act on D2-like receptors (Zheng et al., 1999; Trantham-Davidson et al., 2004).

In the spinal cord, the descending dopaminergic fibre projects from the hypothalamic A11 region (Björklund and Skagerberg, 1979; Skagerberg and Lindvall, 1985; Millan, 2002; Benaroch, 2008), and dopamine can modulate locomotion and nociception (Clemens and Hochman, 2004; Han et al., 2007; Lapointe et al., 2009). In the rat spinal cord, dopamine at concentrations greater than 10 µM activates K+ channels, producing hyperpolarization via D2-like receptors, but not D1-like receptors in substantia gelatinosa neurons, which are located in the superficial laminae of the dorsal horn receiving nociceptive inputs (Tamae et al., 2005; Taniguchi et al., 2011). D1-like receptors are also expressed in the spinal cord (Levant and McCarson, 2001; Zhu et al., 2007). Although it has been reported that dopamine increases AMPA currents via D1-like receptors in the mouse motoneurons (Han and Whelan, 2009), the role of D1-like receptors in afferent transmission remains unclear.

The spinal cord isolated from neonatal rats is a widely-used preparation for investigating spinal functions and drug actions. Electrical stimulation of the dorsal root
elicits a monosynaptic reflex potential (MSR) followed by a slow ventral root potential (sVRP) at the corresponding ventral root. The MSR is A fibre-evoked response mainly mediated by non-NMDA receptors. On the other hand, sVRP is C fibre-evoked polysynaptic response mediated by NMDA and various metabolic receptors such as tachykinin NK receptors in the spinal cord (Akagi et al., 1985; Nussbaumer et al., 1989; Brockmeyer and Kendig, 1995; Faber et al., 1997; Kocsis et al., 2003). The sVRP is believed to reflect nociceptive transmission in the spinal cord based on its electrophysiological and pharmacological features (Akagi and Yanagisawa, 1987; Nussbaumer et al., 1989; Woodley and Kendig, 1991; Faber et al., 1997; Otsuguro et al., 2005). Our laboratory previously reported that dopamine at concentrations of >1 µM depolarized the ventral root and suppressed the MSR (Kitazawa et al., 1985). In the mouse spinal cord, dopamine depresses MSR via D2-like receptors (Clemens and Hochman, 2004). In contrast, there is no information on the effects of dopamine on sVRP. In the current study, the effects of dopamine on spinal cord isolated from the neonatal rat were examined. The results have demonstrated that dopamine at lower concentrations, as well as endogenous dopamine, preferentially depresses sVRP via D1-like receptors.
Methods

Spinal cord preparation

All experimental protocols were approved by the Committee on Animal Experimentation, Graduate School of Veterinary Medicine, Hokkaido University. Every effort was made to minimize animal suffering and to reduce the number of animals used. Wistar rats (0-5 days old) of either sex were used.

Neonatal rats were euthanized by decapitation, and then the spinal cords were isolated. Isolated spinal cord preparations were prepared as previously described (Otsuguro et al., 2006; 2011). The hemisected spinal cord from the lower thoracic through sacral regions was superfused in a recording chamber of 0.5 ml volume with artificial cerebrospinal fluid (ACSF) at a flow rate of approximately 2.5 ml min\(^{-1}\). The temperature of the bath was monitored before and after each recording using a thermometer (CT-1200D, Custom, Tokyo, Japan) and was maintained at 27±2°C. The composition of the ACSF was as follows (mM): NaCl 138; NaHCO\(_3\) 21; NaH\(_2\)PO\(_4\) 0.6; KCl 3.5; CaCl\(_2\) 1.25; MgCl\(_2\) 1.2; glucose 10; gassed with 95% O\(_2\) and 5% CO\(_2\); pH~7.3.

Electrophysiological measurement

Stimulating and recording suction electrodes were placed on the dorsal and ipsilateral
ventral roots (L3-L5), respectively. The dorsal root was stimulated every 2 min by a single square wave pulse (40 V, 200 µs). MSR and sVRP were recorded from the segmental ventral root, and the magnitudes of each were expressed as peak amplitude (mV) and depolarization integral (mV s) over the resting potential of the ventral root, respectively (Figure 1A). The preparation was allowed to equilibrate for 1 h before recordings. In most of the experiments, the inhibitory effects of dopamine, SKF83959, SKF81297 and methamphetamine on spinal reflex potentials were evaluated by measuring the mean of three responses around their maximal effects and the data were expressed as a percentage of the mean of three responses just before application. The time course of the magnitude of the MSR and sVRP was expressed as a percentage of the mean of the first five responses. Electrical responses were detected by a high gain amplifier (MEZ-8300, Nihon Kohden, Tokyo, Japan) with low-pass filter at 10 kHz. MSR was recorded using a thermal arraycorder (WR7900, Graftec, Yokohama, Japan) with a sampling time of 80 µs. sVRP were digitized by an analog/digital converter (PowerLab, ADInstruments, Castle Hill, Australia) with a sampling time of 10 ms. Data were stored in a personal computer and analyzed with LabChart 6 software (ver. 6.0, ADInstruments).
The oligonucleotide primers used for amplifying dopamine receptor subtype gene sequences (GenBank accession number) and its expected product size were as follows:

D1 (M35077) forward: 5’-CAGTCCATGCCAAGAATTGCC-3’ and reverse: 5’-
AATCGATGCAGAATGGCTGGG-3’ (225 bp); D2 (D2S: M36831, D2L: X53278) forward:
5’-GCAGTCGAGCTTTTCAGAGCC-3’ and reverse: 5’-TCTGCGGCTCATCGTCTTGG-3’
(317 and 404 bp, respectively); D3 (X53944) forward: 5’-
TCCTGTCTGAGGCTCATCC-3’ and reverse: 5’-TCGAAGTGGTACTCCCCCGAG-3’ (381
bp); D4 (M84009) forward: 5’-GATGTGTTGGACGCCTTTTCT-3 and reverse: 5’-
TCGGCATTGAAGATGGTGTA-3’ (150 bp); D5 (NM_012768) forward:
5’-ACCAAGACACGGTCTTCCAC-3’ and reverse: 5’-CACAGTCAAGCTCCAGACA-3’
(189 bp); β-Actin (V01217) forward: 5’-TGTCACCAACTGGGACGATA-3’ and reverse:
5’-ACCCCTCATAGTAGGGCCACAG-3’ (280 bp). Total RNA was extracted from the lumbar
region of the spinal cord and its dorsal root ganglion (DRG) using TRI Reagent
(Sigma-Aldrich, Saint Louis, MO, USA) and then treated with DNase I (Invitrogen,
Carlsbad, CA, USA). First strand cDNA synthesis and subsequent amplification were
performed using a PrimeScript One Step RT-PCR Kit (Ver. 2, Takara Bio, Otsu, Japan).
PCR reactions were preceded by incubation at 94°C for 2 min and consisted of 94°C for
30 s, followed by 57°C (D2, D5 and β-actin), 60°C (D4) or 65°C (D1, D3) for 30 s, and 72°C for 60 s for 30 (D1, D2, D5 and β-actin), 34 (D3) and 36 (D4) cycles. Amplified products were separated and analyzed by 2.0% agarose gel electrophoresis containing ethidium bromide and visualized under UV light.

*Measurement of dopamine and 5-HT concentration*

The concentrations of dopamine and 5-HT were determined according to the method of Ito *et al.* (2001) with some modifications. Rat spinal cord from the lower thoracic through lumbar regions was isolated from five littermates. After removal of all roots and DRGs, the spinal cord was sliced into several pieces and then they were equilibrated in ACSF for 1 h at 35°C. After incubation for 30 min with fresh ACSF, the tissues were treated for 10 min with methamphetamine (30 µM) and then incubated for an additional 30 min with fresh ACSF. Incubation media from before and after treatment with methamphetamine was stored on ice for the measurement of 5-HT. For the measurement of dopamine, the sample solution was treated with alumina to purify and concentrate the dopamine (Anton and Sayre, 1962). Isoproterenol (1 µM) was used as an internal standard.

The samples were applied to an HPLC system with an ODS column.
(EICOMPAK SC-5ODC, 3.0 ×150 mm, EICOM, Kyoto, Japan) equipped with an 
electrochemical detector (ECD-300, EICOM, Kyoto, Japan). The mobile phase consisted 
of 100 mM citric buffer (pH 3.5), 19% methanol, 5 mg l⁻¹ EDTA Na₂ and 190 mg l⁻¹ 
sodium octasulfonic acid. The flow rate was 0.5 ml min⁻¹. The amounts of dopamine and 
5-HT were expressed relative to tissue wet weight (fmol mg⁻¹).

Data analysis

Results were expressed as means±SEM. Statistical comparisons between two groups 
were performed by paired or unpaired Student’s t-test. A P value of less than 0.05 was 
considered significant.

Drugs

Haloperidol was purchased from Pfizer Japan (Tokyo, Japan). (S),9(R)-(-)-Bicuculline 
methobromide and 5-hydroxytryptamine creatinine sulfate (5-HT) were from 
Sigma-Aldrich (St. Louis, MO, USA). 3-Hydroxytyramine hydrochloride (dopamine) was 
from Tokyo Chemical (Tokyo, Japan). dl-Isoproterenol hydrochloride and strychnine 
sulfate were from Wako Pure Chemical (Osaka, Japan). Ketanserin tartrate, LE300, 
raclopride, SCH23390 hydrochloride, SKF81297 hydrobromide and SKF83959
hydrobromide were from Tocris Bioscience (Bristol, UK). Methamphetamine hydrochloride was from Dainippon Sumitomo Pharma (Osaka, Japan). Atipamezole hydrochloride was supplied from Orion (Espoo, Finland). Naloxone hydrochloride was from Daiichi Sankyo (Tokyo, Japan). Drugs and molecular target nomenclature follows Alexander et al. (2009).

**Results**

*Effects of dopamine on reflex potentials in rat spinal cord*

The effects of dopamine on spinal reflex potentials evoked by electrical stimulation were measured every 2 min. Bath-application of dopamine (1 µM) rapidly suppressed the sVRP without any effect on MSR (Figure 1B). This inhibitory effect of dopamine was often accompanied by suppression of spontaneous activity without changes in baseline ventral root potential. The dopamine-evoked depression of sVRP was maintained during application for 10 min followed by immediate recovery after washout of the drug. As shown in Figure 1C, repeated application of dopamine inhibited sVRP to the same extent (1st: 64.5±3.9%, n=6; 2nd: 64.5±3.7%, n=6).

The application of dopamine (0.01–1 µM) inhibited sVRP but not MSR, in a concentration-dependent manner without any effect on baseline potential (Figure 2). As
previously reported (Kitazawa et al., 1985), at a higher concentration (3 µM), dopamine
slightly suppressed MSR and depolarized the baseline ventral root potential, and this
was accompanied by increases in spontaneous activity (Figure 2B). The
concentration-response curve for sVRP inhibition by dopamine was biphasic with a first
phase at concentrations of 300 nM or less and a second phase at concentration of more
than 300 nM (Figure 2C and D).

Dopamine-evoked depression of sVRP was mediated by D1-like receptors

The expression of dopamine receptor subtypes in the spinal cord and DRG of neonatal
rats was examined by RT-PCR. The mRNA expression of all receptor subtypes (D1, D2,
D3, D4 and D5) was detected in the spinal cord. In the DRG, on the other hand, only D2
and D4 receptor mRNA were detected (Figure 3).

The effects of dopamine receptor antagonists on the depression of sVRP in
response to dopamine were investigated (Figure 4). Pre-treatment with SCH23390 (1
µM), a D1-like receptor antagonist, for 20 min resulted in gradual decrease in MSR
(71.0±10.7%, n=8) but not sVRP (110.5±5.0%, n=8). In the presence of SCH23390, the
inhibition of sVRP induced by dopamine (1 µM) was largely attenuated (Figure 4A).
Dopamine-evoked depression of sVRP was also attenuated by LE300 (5 µM), another
D1-like receptor antagonist (Figure 4B). Although treatment with raclopride (5 µM), a
d2-like receptor antagonist, also resulted in a significant decrease of the
dopamine-evoked depression of sVRP, haloperidol (1 µM), another D2-like receptor
antagonist, had no effect on it (Figure 4C). LE300, haloperidol and raclopride had no
effect on MSR (data not shown). These results suggested that D1-like receptors are
involved in sVRP inhibition in response to dopamine. It was next examined whether the
effect of dopamine on the spinal cord was mimicked by SKF83959 and SKF81297,
D1-like receptor agonists. Similar to dopamine, SKF83959 (1 µM) and SKF81297 (1µM)
suppressed the sVRP without any effects on MSR (Figure 5A and B) or baseline ventral
root potential. Inhibition of sVRP in responses to SKF83959 was also effectively
decreased by SCH23390 (Figure 5C and D). Unlike dopamine, however, the effect of
SKF81297 was irreversible until 1 hr after washout (data not shown). Therefore, we
examined the effect of SCH23390 on SKF81297-evoked depression in separate
preparations. Inhibition of sVRP in response to SKF81297 was abolished by SCH23390
(Figure 5D).

Characterization of dopamine-evoked depression of sVRP

Several reports have indicated that dopamine enhances inhibitory transmissions such
as those mediated by GABA and glycine in the CNS (Porras and Mora, 1993; Radnikow and Misgeld, 1998; Seamans et al., 2001; Trantham-Davidson et al., 2004). We next examined the effects of bicuculline and strychnine, GABA<sub>A</sub> and glycine receptor antagonists, respectively, on sVRP inhibition in response to dopamine (Figure 6). Since strychnine and bicuculline markedly increased the amplitude of the sVRP, the inhibitory effect of dopamine was evaluated as a percentage of the responses just before the first application. Strychnine (0.5 µM) increased sVRP to 130.6±0.4% (n=6). In the presence of strychnine, dopamine (1µM) decreased sVRP by 18.7±0.4% (n=6), which was less than the control (38.0±2.8%, n=6, P<0.01, paired Student’s t-test). Bicuculline (3 µM) also increased sVRP to 188.2±20.4% (n=6). In the presence of bicuculline, dopamine decreased sVRP by 21.2±5.6% (n=6), which was not significantly different from the control (34.5±2.2%, n=6). Naloxone (1 µM), an opioid receptor antagonist, also increased sVRP to 117.4±3.7% (n=6). Dopamine-evoked depression of sVRP (41.3±2.8% inhibition, n=6) was unaffected by naloxone (42.7±7.7% inhibition, n=6).

*Methamphetamine-evoked depression of reflex potentials via dopamine and 5-HT release*

To investigate the effect of endogenous dopamine on the spinal cord, the spinal cord preparations were treated with methamphetamine, an endogenous dopamine releaser.
Treatment with methamphetamine (10 µM) for 10 min gradually depressed sVRP (Figure. 7A). Unlike dopamine, methamphetamine also depressed MSR, and these inhibitory effects on MSR and sVRP continued even after washout of the drug. The level of depression reached a trough, followed by gradual recovery to control levels, approximately 10 and 20 min after washout, respectively. Methamphetamine (3, 10 and 30 µM) depressed both MSR and sVRP in a concentration-dependent manner (Figure. 7B and C). Methamphetamine at a low concentration (3 µM) had little, if any, effect on reflex potentials; the highest concentration (30 µM) caused more potent and long-lasting depressions of MSR and sVRP than 10 µM methamphetamine.

Repeated application of methamphetamine (10 µM) for 10 min after an interval of 40 min depressed reflex potentials to the same extent for MSR (1st: 57.1±12.0%; 2nd: 52.8±11.6%, n=6) and sVRP (1st: 61.6±9.3%; 2nd: 55.8±11.5%, n=6). As shown in Figure. 8, the inhibition of sVRP by methamphetamine was attenuated by the D1-like receptor antagonists SCH23390 (1 µM) and LE300 (5 µM) but not by the D2-like receptor antagonists haloperidol (1 µM) and raclopride (5 µM). On the other hand, the depression of MSR by methamphetamine was abolished by LE300 and attenuated by haloperidol but not by raclopride (Figure 9). We could not analyze the effect of SCH23390 on methamphetamine-evoked depression of MSR because SCH23390 by itself depressed
the MSR as mentioned above.

In addition to dopamine, methamphetamine releases other monoamines such as 5-HT and noradrenaline (Ono and Fukuda, 1984; Seiden et al., 1988; Ono et al., 1991; Fleckenstein et al., 2000). Therefore, the effects of ketanserin, a 5-HT2A/2C receptor antagonist, and atipamezole, an α2 adrenoceptor antagonist, on MSR inhibition in response to methamphetamine were examined. Ketanserin (1 µM) inhibited the methamphetamine-evoked depression of MSR but not sVRP (Figure 10), while atipamezole (1 µM) had no effect on the depression of either reflex potentials by methamphetamine. Ketanserin and atipamezole by themselves had no effect on MSR and sVRP (data not shown). We also examined whether methamphetamine induced the release of these monoamines from the spinal cord. As shown in Figure 11, methamphetamine (30 µM) significantly increased the release of dopamine and 5-HT. The amount of 5-HT release was 5 or more times greater than that of dopamine release. These results suggest that methamphetamine releases 5-HT and dopamine, which depresses MSR and sVRP, respectively.

**Discussion and conclusions**

In the current study, dopamine depressed sVRP in the isolated spinal cords of neonatal
rats via the activation of D1-like receptors. Methamphetamine also depressed sVRP through the release of endogenous dopamine. These effects are suggested to contribute to functional regulation of spinal cord by dopamine released from the descending fibre.

It has been reported that at a concentration of 1 µM, dopamine depresses the MSR, representing monosynaptic transmission evoked by an A fibre activation, in the mouse spinal cord via D2-like receptors (Clemens and Hochman, 2004); at higher concentrations (>1 µM), dopamine depolarizes baseline ventral root potential and depresses MSR in the rat spinal cord (Kitazawa et al., 1985). As shown in the current study, in addition to the inhibition of MSR, lower concentrations (<1 µM) of dopamine depressed sVRP without any effects on MSR and baseline level potential.

Methamphetamine, an endogenous dopamine releaser, also depressed sVRP. Inhibition by both agents was reversed by the D1-like receptor antagonists. Moreover, the D1-like receptor agonists mimicked the inhibitory effect of dopamine on sVRP. Taken together, these results indicate that endogenous dopamine effectively depresses sVRP via D1-like receptors. Raclopride, a D2-like receptor antagonist, slightly decreased the effect of dopamine, implying the additional contribution of D2-like receptors to the depression. However, it is unlikely that D2-like receptors are mainly contributed to the inhibition by low concentrations (<1 µM) of dopamine because the methamphetamine-evoked
depression was only slightly decreased by raclopride. In addition, another D2-like receptor antagonist, haloperidol, failed to attenuate both the dopamine- and methamphetamine-evoked sVRP depression. On the other hand, in the presence of SCH23390, the inhibitory effect of SKF81297 on sVRP was abolished, while the effect of dopamine was partially remained. These results also suggest the contribution of distinct receptors from D1- and D2-like receptors to the effects of dopamine. Further investigation is needed to determine these receptors.

The depression of sVRP by dopamine suggests an antinociceptive effect on the spinal cord, as sVRP is believed to reflect C-fibre-evoked nociceptive transmission (Akagi et al., 1985; Faber et al., 1997), which can be depressed by analgesics such as opioids or α2-adrenoceptor agonists (Yanagisawa et al., 1984; Nussbaumer et al., 1989; Kendig et al., 1991; Faber et al., 1998; Otsuguro et al., 2005). However, in pain tests in vivo, the antinociceptive effects of D1-like receptors are inconsistent. In the mouse (Zarrindast et al., 1999) and rat formalin test (Munro, 2007), systemic administration of D1-like receptor agonists preferentially suppressed nociceptive behavior in phase II (chronic pain) compared to phase I (acute pain), while D2-like receptor agonists were effective in both phases. On the other hand, dopamine or its analogues have been shown to cause antinociception via D2-like but not D1-like receptors in the rat tail-flick test.
(Barasi and Duggal, 1985; Liu et al., 1992), von Frey test (Tamae et al., 2005) and carrageenan-induced inflammatory pain (Gao et al., 2001). Further studies are needed to define the role of D1-like receptors in nociceptive transmission in the spinal cord.

Unlike dopamine and the D1-like receptor agonists, methamphetamine depressed sVRP and MSR to a similar extent. The depression of MSR was inhibited by dopamine receptor antagonists (LE300 and haloperidol). However, it is unlikely that dopamine is involved in this effect because MSR was not inhibited by dopamine and the D1-like receptor agonists at concentrations that inhibited sVRP. The depression of MSR was inhibited by ketanserin, a 5-HT2A/2C antagonist, but not by raclopride, a selective D2-like receptor antagonist. Methamphetamine releases not only dopamine but also 5-HT (Azzaro and Rutledge, 1973; Seiden et al., 1988; Higuchi et al., 2008), and this was also the case in the current study. The higher concentration of 5-HT than dopamine may be due to the extensive projection of serotonergic fibres throughout the spinal cord (Millan, 2002). In addition, it has also been reported that 5-HT depresses MSR in the rat spinal cord (Yomono et al., 1992; Wallis et al., 1993). It seems likely, therefore, that 5-HT released by methamphetamine inhibited MSR in the neonatal rat spinal cord. The inhibitory effects of SCH23390 on MSR may be mediated via serotonergic mechanisms because of its agonistic effects for serotonergic systems (Briggs et al., 1991; Millan et al.,
Ketanserin is a 5-HT$_{2A/2C}$ receptor antagonist (Hartman and Northup, 1996). In addition, the demonstrated affinities of LE300 and haloperidol to 5-HT$_{2A}$ receptors (Fontenla et al., 1994; Seeman and Tol, 1994; Witt et al., 2000; Rostom et al., 2001; El-Subbagh et al., 2002) suggest that 5-HT released by methamphetamine inhibits MSR via 5-HT$_{2A}$ receptors.

sVRP is evoked by transmission from primary afferent fibres to motoneurons via interneurons. These neuronal activities are modulated by inhibitory inputs (Akagi and Yanagisawa, 1987; Nussbaumer et al., 1989), a process in which GABAergic and glycinergic interneurons play a key role (Akagi and Yanagisawa, 1987; Otsuguro et al., 2006). There are several possible mechanisms of D1-like receptor-evoked sVRP inhibition, including presynaptic inhibition of excitatory transmitter release, presynaptic facilitation of inhibitory transmitter release, and postsynaptic inhibition. Our results showed that D1-like receptor mRNA are expressed in the spinal cord but not in the DRG, suggesting that dopamine inhibits sVRP by acting on interneurons and/or motoneurons but not by inhibiting excitatory transmitter release from the endings of primary afferents.

Endogenous opioids have been implicated in spinal antinociception by dopamine (Kang et al., 1998; Hu et al., 1999). However, in the current study, blocking of
opioid receptors did not affect the depression of sVRP. D1-like receptors stimulate adenylyl cyclase (Missale et al., 1998). On the other hand, D1-like receptors also stimulate phospholipase C (Undie and Friedman, 1990), and SKF83959 has been reported to selectively activate phosphatidylinositol (PI)-linked D1-like receptors in the rat brain (Jin et al., 2003; Chu et al., 2010). Therefore, PI response may be involved in the sVRP inhibition via D1-like receptors in the neonatal rat spinal cord. In the current study, blocking GABA_A and glycine receptors appeared to attenuate the inhibition of sVRP by dopamine, suggesting that the postsynaptic activation of GABAergic and/or glycine inhibitory neurons by dopamine might at least partly contribute to the sVRP inhibition. However, we cannot exclude the possibility that the inhibitory effects of dopamine are underestimated due to the substantial increase in the amplitude of sVRP induced by strychnine or bicuculline alone. Alternatively, these antagonists may preferentially enhance the activities of neurons that do not receive dopaminergic depression. Further studies are needed to clarify the cellular mechanism of sVRP inhibition evoked by dopamine in the spinal cord.

**Acknowledgements**

This work was supported by a Grant-in-Aid for Scientific Research from the Japan
Society for the Promotion of Science.

References


El-Subbagh H, Wittig T, Decker M, Elz S, Nieger M, Lehmann J (2002). Dopamine-serotonin receptor ligands. Part IV [1]: synthesis and pharmacology of
novel 3·benzazecines and 3·benzazonines as potential 5·HT_{2A} and dopamine receptor ligands. Arch Pharm (Weinheim) 335: 443·448.


Han P, Nakanishi ST, Tran MA, Whelan PJ (2007). Dopaminergic modulation of spinal


benz[\textit{d}indolo[2,3-\textit{g}]azecine derivative LE 300. Arch Pharm (Weinheim) 334: 241-247.


differential D1 versus D2 dopamine receptor regulation of inhibition in prefrontal

Undie AS, Friedman E (1990). Stimulation of a dopamine D1 receptor enhances inositol

Wallis DI, Wu J, Wang X (1993). Descending inhibition in the neonate rat spinal cord is

Witt T, Hock FJ, Lehmann J (2000). 7-Methyl-6,7,8,9,14,15-hexahydro-5'H-
benz[delta]indolo[2,3-g]azecine: a new heterocyclic system and a new lead compound for

Woodley SJ, Kendig JJ (1991). Substance P and NMDA receptors mediate a slow

the effects of some antinociceptive compounds. Eur J Pharmacol 106, 231-239.

inhibition of monosynaptic reflex in the neonatal rat spinal cord. Neuroscience 47:
521-531.

Zarrindast MR, Nassiri-Rad S, Pazouki M (1999). Effects of dopaminergic agents on


Conflict of interest

None.
Figure legends

Figure 1. Effect of dopamine on spinal reflex potentials in neonatal rat

A, representative traces of reflex potentials evoked by electrical stimulation (arrow head). The magnitude of monosynaptic reflex potential (MSR) and slow ventral root potential (sVRP) were measured as the peak amplitude (mV) and the integral of depolarization (mV·s) over the resting potential, respectively. B, representative traces of MSR (upper panel) and sVRP (lower panel) evoked by electrical stimulation every 2 min (arrow heads). Dopamine (DA, 1 µM) was applied for 10 min. Dot line indicates the baseline ventral root potential. C, depression of sVRP but not MSR by repeated application of dopamine (1 µM).

Figure 2. Concentration-response relationship of effects of dopamine on spinal reflex potential

A, representative traces of monosynaptic reflex potential (MSR, upper panel) and slow ventral root potential (sVRP, lower panel) in the presence of dopamine. Dopamine (DA, 0.01-3 µM) was cumulatively applied to the spinal cord. B, depolarization of ventral root potential evoked by DA (3 µM). Dot line indicates baseline ventral root potential. C,
time course of dopamine-evoked depression of sVRP. D, concentration-response curves for MSR and sVRP in the presence of dopamine. Data represent means±SEM (n=6).

Figure 3. Expression of dopamine receptor subtypes in spinal cord

RT-PCR analysis of dopamine D1, D2, D3 (upper panel), D4, D5 and β-actin mRNA (lower panel) in rat spinal cord (SC) and DRG.

Figure 4. Effects of D1-like and D2-like receptor antagonists on dopamine-evoked depression of sVRP

A, B, dopamine (DA, 1 μM) was applied to the spinal cord for 10 min (control). Dopamine was again applied in the presence of SCH23390 (SCH, 1 μM, A) and LE300 (LE, 5 μM, B) after pretreatment for 20 min. Representative traces of slow ventral root potential (sVRP) are shown in the right panels. C, summary of the effects of D1-like and D2-like receptor antagonists, SCH23390, LE300, haloperidol (halop, 1 μM) and raclopride (raclo, 5 μM), on dopamine-evoked depression of sVRP. Data represent means ±SEM (n=6–8). *P< 0.05 vs. control (paired Student’s t test).

Figure 5. Depression of sVRP by the D1-like receptor agonist SKF83959
A and B, SKF83959 (1 µM, A) and SKF81297 (1 µM, B) was applied to the spinal cord. The numbers in the representative traces of monosynaptic potential (MSR, upper panel) and slow ventral root potential (sVRP, middle panel) correspond to those in the lower panel. C, SKF83959 (SKF, 1 µM)-evoked depression of sVRP in the presence or absence of SCH23360 (SCH, 1 µM). D, summary of the effect of SCH23360 (SCH, 1 µM) on SKF83959 (1 µM)- and SKF81297 (1 µM)-evoked depression of sVRP. Data represent means±SEM (n=6). **P< 0.01 vs. in the absence of SCH23360 (paired Student's t-test).

**Figure 6. Effects of glycine and GABA<sub>A</sub> receptor antagonists on dopamine-evoked depression of sVRP**

A and B, effects of dopamine (DA, 1 µM) in the presence and absence of strychnine (stry, 0.5 µM, A) and bicuculline (bic, 3 µM, B). Representative traces of slow ventral root potential (sVRP) are shown in the right panels.

**Figure 7. Depression of MSR and sVRP by the endogenous dopamine releaser methamphetamine**

A, methamphetamine (MA, 10 µM) was applied for 10 min to the spinal cord. The numbers in the representative traces of monosynaptic potential (MSR, upper panel) and
slow ventral root potential (sVRP, middle panel) correspond to those in the lower panel.

B and C, concentration-dependent depression of MSR (B) and sVRP (C) by methamphetamine (MA, 3, 10 and 30 µM). Data represent means±SEM (n=6).

**Figure 8. Effects of D1-like and D2-like receptor antagonists on methamphetamine-evoked depression of sVRP**

A and B, methamphetamine (MA, 10 µM) was applied to the spinal cord for 10 min (control). Methamphetamine was again applied in the presence of SCH23390 (SCH, 1 µM, A) or LE300 (LE, 5 µM, B) after pretreatment for 20 min. Representative traces of slow ventral root potential (sVRP) are shown in the right panels. C, summary of the effects of D1-like and D2-like receptor antagonists, SCH23390, LE300, haloperidol (halop, 1 µM) and raclopride (raclø, 5 µM), on methamphetamine-evoked depression of sVRP. Data represent means±SEM (n=6-7). *P< 0.05, **P< 0.01 vs. control (paired Student’s t-test).

**Figure 9. Effects of D1-like and D2-like receptor antagonists on methamphetamine-evoked depression of MSR**

A-C, methamphetamine (MA, 10 µM) was applied to the spinal cord for 10 min (control).
Methamphetamine was again applied in the presence of LE300 (LE, 5 µM, A), haloperidol (halop, 1 µM, B) or raclopride (raclo, 5 µM, C) after pretreatment for 20 min. Representative traces of monosynaptic potential (MSR) are shown in the right panels. D, summary of the effects of D1-like and D2-like receptor antagonists, LE300, haloperidol and raclopride, on methamphetamine-evoked depression of MSR. Data represent means ±SEM (n=6-7). **P< 0.01 vs. control (paired Student’s t-test).

**Figure 10. Effects of 5-HT₂ and α₂ receptor antagonists on methamphetamine-evoked depression of MSR and sVRP**

A and C, methamphetamine (MA, 10 µM) was applied to the spinal cord for 10 min (control). Methamphetamine was again applied in the presence of ketanserin (keta, 10 µM) after pretreatment for 20 min. Representative traces of monosynaptic potential (MSR, A) and slow ventral root potential (sVRP, C) are shown in the right panels. B and D, summary of the effects of ketanserin and atipamezole (atipa, 1 µM) on methamphetamine-evoked depression of MSR (B) and sVRP (D). Data represent means ±SEM (n=6-8). *P< 0.05 vs. control (paired Student’s t-test).

**Figure 11. Methamphetamine-evoked dopamine and 5-HT release from spinal cord**
A and B, the amount of dopamine (DA, A) and 5-HT (B) release for 30 min before (pre) and after treatment with methamphetamine (MA, 30 µM) for 10 min. Data represent means±SEM (n=3-4). *P< 0.05 vs. control (paired Student’s t test).
Fig. 4

A

B

C

**sVRP (%)**

- **DA**
- **pre**
- **SCH**
- **LE**
- **0.5 mV 10 s**

**Time (min)**

- Control
- SCH
- LE
- SCH + DA
- DA
- pre
- LE + DA

**sVRP (inhibition %)**
**A**

MSR

sVRP

**B**

MSR

sVRP

**C**

MSR

sVRP

**D**

SCH
Fig. 6

A

DA 1 µM

strychnine 0.5 µM

B

bicuculline 3 µM

DA 1 µM

sVRP (%)

time (min)

DA

pre

1 mV

stry

stry

bic

bic

+ DA

+ DA

+ DA

10 s

10 s

10 s
Fig. 8

A

B

C

sVRP (%) vs time (min)

SCH

control

MA

pre

LE

control

0.5 mV

10 s

SCH

MA

+ MA

LE

+ MA

sVRP (%)

control

SCH

LE

control

halop

control

dalc

sVRP (inhibition %)

control

SCH

control

LE

control

halop

control

dalc

* P < 0.05

** P < 0.01
Fig. 10

A

MSR (%)

control
keta
keta + MA

time (min)

B

MSR (inhibition %)

control keta control atipa

C

sVRP (%)

control keta

D

sVRP (inhibition %)

control keta control atipa
Fig. 11

A

DA release (fmol mg\(^{-1}\))

<table>
<thead>
<tr>
<th></th>
<th>pre</th>
<th>MA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>*</td>
</tr>
</tbody>
</table>

B

5-HT release (fmol mg\(^{-1}\))

<table>
<thead>
<tr>
<th></th>
<th>pre</th>
<th>MA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>*</td>
</tr>
</tbody>
</table>